2-(9H-芴-9-甲氧基羰基氨基)-3-(4-硝基-苯基)-丙酸 | 250740-52-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(9H-芴-9-甲氧基羰基氨基)-3-(4-硝基-苯基)-丙酸
• 中文别名: N-FMOC-DL-4-硝基苯丙氨酸；Fmoc-4-硝基-DL-苯丙氨酸
• 英文名称: N-[(9H-fluoren-9-ylmethoxy)carbonyl]-4-nitrophenylalanine
• 英文别名: N-α-Fmoc-Phe(NO2)-OH；Fmoc-4-nitrophenylalanine；2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(4-nitrophenyl)propanoic Acid
• CAS: 250740-52-4
• 化学式: C₂₄H₂₀N₂O₆
• 分子量: 432.433
• InChiKey: RZRRJPNDKJOLHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(9H-芴-9-甲氧基羰基氨基)-3-(4-硝基-苯基)-丙酸 在 甲醇 、 sodium tetrahydroborate 作用下， 生成 3-(4-aminophenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
  参考文献：
  名称：

  WO2023/247968

  摘要：

  公开号：
• 作为产物：
  描述：

  4-硝基-DL-苯丙氨酸 、 氯甲酸-9-芴基甲酯 在 碳酸氢钠 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 2-(9H-芴-9-甲氧基羰基氨基)-3-(4-硝基-苯基)-丙酸
  参考文献：
  名称：

  WO2023/247968

  摘要：

  公开号：

文献信息

• Inhibitors of &agr;4&bgr;1 mediated cell adhesion
  申请人：Pharmacia & Upjohn Company

  公开号：US06685617B1

  公开（公告）日：2004-02-03

  The present invention relates to compound of formula (I), that are potent inhibitors of &agr;4&bgr;1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. Specifically, the molecules of the present invention can be used for treating or preventing &agr;4&bgr;1 adhesion mediated conditions in a mammal such as a human. This method may comprise administering to a mammal or a human patient an effective amount of the compound or composition as explained in the present specification.

  本发明涉及式(I)的化合物，它们是α4β1介导的对VCAM或CS-1的黏附的有效抑制剂，可用于治疗炎症性疾病。具体来说，本发明的分子可用于治疗或预防哺乳动物，如人类，中的α4β1介导的黏附状况。该方法可能包括向哺乳动物或人类患者施用本说明书中所述的化合物或组合物的有效量。
• Heteroaryl nitriles
  申请人：——

  公开号：US20030212097A1

  公开（公告）日：2003-11-13

  The present invention relates to compound of formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 and n are as defined in the description and claims and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for the treatment of diseases which are associated with cysteine proteases such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis, atherosclerosis, myocardial infarction, angina pectoris, instable angina pectoris, stroke, plaque rupture, transient ischemic attacks, amaurosis fugax, peripheral arterial occlusive disease, restenosis after angioplasty and stent placement, abdominal aortic aneurysm formation, inflammation, autoimmune disease, malaria, ocular fundus tissue cytopathy and respiratory disease.

  本发明涉及以下式（I）的化合物 1 其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 和n如描述和索赔中所定义，并且其药学上可接受的盐和/或药学上可接受的酯。这些化合物可用于治疗与半胱氨酸蛋白酶相关的疾病，如骨质疏松症、骨关节炎、类风湿关节炎、肿瘤转移、肾小球肾炎、动脉粥样硬化、心肌梗死、心绞痛、不稳定性心绞痛、中风、斑块破裂、短暂性缺血发作、短暂性视网膜动脉阻塞、外周动脉闭塞症、血管成形术后再狭窄和支架植入术后再狭窄、腹主动脉瘤形成、炎症、自身免疫疾病、疟疾、眼底组织细胞病变和呼吸道疾病。
• Indole nitriles
  申请人：——

  公开号：US20040077646A1

  公开（公告）日：2004-04-22

  Compounds of the formula (I) 1 wherein m, n, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein, together with methods for making the compounds and using the compounds for treatment of diseases or conditions mediated by Cathepsin K.

  式(I)的化合物，其中m、n、R1、R2、R3、R4、R5和R6如本文所述，以及制备这些化合物的方法和利用这些化合物治疗由Cathepsin K介导的疾病或症状的方法。
• Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
  申请人：Flohr Stefanie

  公开号：US20050004131A1

  公开（公告）日：2005-01-06

  Substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.

  取代的六氢吡嗪[1,2-a]嘧啶-4,7-二酮衍生物，其制备方法及其用作药物。本发明涉及取代的六氢吡嗪[1,2-a]嘧啶-4,7-二酮衍生物以及其生理耐受盐和生理功能衍生物。描述了具有以下式I的化合物，其中基团具有所述含义，以及其生理耐受盐和制备它们的方法。这些化合物例如适用于作为厌食剂。
• 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors
  申请人：Lassoie Marie-Agnes

  公开号：US20080064720A1

  公开（公告）日：2008-03-13

  The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and atherosclerosis. Formula (I): wherein X is N or CH.

  本发明涉及公式(I)的2,6-喹啉基和2,6-萘基衍生物，其制备方法，含有它们的制药组合物以及它们作为药物治疗VLA-4依赖性炎症性疾病的用途，例如哮喘、过敏性鼻炎、鼻窦炎、结膜炎、食物过敏、银屑病、荨麻疹、瘙痒、湿疹、类风湿性关节炎、炎症性肠病、多发性硬化和动脉粥样硬化。公式(I)中，X为N或CH。